Tali Azenkot • UCSD Profiles (original) (raw)

  1. High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma. Melanoma Res. 2026 Apr 30. Azenkot T, Nikanjam M, Mhatre S, Mullen JT, Barkauskas DA, McKay RR, Baumgartner JM, Daniels GA. PMID: 42070986.
    View in: PubMed Mentions:
  2. Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38). J Immunother Cancer. 2025 Oct 20; 13(10). Patel SP, Othus M, Chae YK, Azenkot T, Wagner MJ, Threlkel S, Farley JH, Magner CM, Chen HX, Sharon E, Ryan CW, Blanke C, Kurzrock R. PMID: 41120126; PMCID: PMC12542749.
    View in: PubMed Mentions: Fields:
    Translation:HumansCTClinical Trials
  3. Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC). Expert Opin Pharmacother. 2025 Aug; 26(11-12):1271-1278. Herrmann A, Azenkot T, Hilburn V, Bazhenova L. PMID: 40696796.
    View in: PubMed Mentions: Fields:
    Translation:HumansAnimals
  4. Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473590. Azenkot T, Rivera DR, Stewart MD, Patel SP. PMID: 40403202.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  5. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 01; 65(1):69-77. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. PMID: 37801340.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  6. Isolated Finger Compartment Syndrome Following Crush Injury. J Gen Intern Med. 2023 12; 38(16):3636-3637. Azenkot T, Aronowitz PB. PMID: 37723367; PMCID: PMC10713936.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  7. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. Leuk Res. 2023 08; 131:107331. Khanna V, Azenkot T, Liu SQ, Gilbert J, Cheung E, Lau K, Pollyea DA, Traer E, Jonas BA, Zhang TY, Mannis GN. PMID: 37263072.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  8. Tobacco and Cannabis Use During and After Pregnancy in California. Matern Child Health J. 2023 Jan; 27(1):21-28. Azenkot T, Dove MS, Fan C, Valencia CV, Tong EK, Schwarz EB. PMID: 36192518; PMCID: PMC9529159.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansAnimals
  9. Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia. Cancers (Basel). 2022 Jul 26; 14(15). Azenkot T, Jonas BA. PMID: 35892893; PMCID: PMC9330895.
    View in: PubMed Mentions: 5
  10. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 08; 119:106885. Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 35738024.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCells
  11. Special Considerations for Women of Reproductive Age on Anticoagulation. J Gen Intern Med. 2022 08; 37(11):2803-2810. Azenkot T, Schwarz EB. PMID: 35641728; PMCID: PMC9411301.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  12. Anticoagulant Prescriptions Provided in US Ambulatory Practice, 2014 to 2016. J Gen Intern Med. 2022 10; 37(13):3515-3517. Azenkot T, Chatterton B, Schwarz EB. PMID: 35411531; PMCID: PMC9550935.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  13. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 06 01; 97(6):E191-E194. Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. PMID: 35266185.
    View in: PubMed Mentions: 6 Fields:
    Translation:Humans
  14. Hospital-acquired influenza in the United States, FluSurv-NET, 2011-2012 through 2018-2019. Infect Control Hosp Epidemiol. 2022 10; 43(10):1447-1453. Cummings CN, O'Halloran AC, Azenkot T, Reingold A, Alden NB, Meek JI, Anderson EJ, Ryan PA, Kim S, McMahon M, McMullen C, Spina NL, Bennett NM, Billing LM, Thomas A, Schaffner W, Talbot HK, George A, Reed C, Garg S. PMID: 34607624.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansPHPublic Health
  15. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Rev Hematol. 2021 05; 14(5):407-417. Othman TA, Tenold ME, Moskoff BN, Azenkot T, Jonas BA. PMID: 34076549; PMCID: PMC8515853.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  16. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. Future Oncol. 2021 Aug; 17(23):2989-3005. Othman TA, Azenkot T, Moskoff BN, Tenold ME, Jonas BA. PMID: 34024158.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  17. Cytomegalovirus shedding from breastmilk and mucosal sites in healthy postpartum women: A pilot study. J Med Virol. 2019 05; 91(5):894-898. Azenkot T, Zaniello B, Green ML, Selke S, Huang ML, Magaret A, Wald A, Johnston C. PMID: 30578684; PMCID: PMC6402967.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCells
  18. BCG vaccination induces HIV target cell activation in HIV-exposed infants in a randomized trial. JCI Insight. 2017 04 06; 2(7):e91963. Gasper MA, Hesseling AC, Mohar I, Myer L, Azenkot T, Passmore JS, Hanekom W, Cotton MF, Crispe IN, Sodora DL, Jaspan HB. PMID: 28405623; PMCID: PMC5374072.
    View in: PubMed Mentions: 13 Fields:
    Translation:HumansCellsCTClinical Trials
  19. Sugar-induced cephalic-phase insulin release is mediated by a T1r2+T1r3-independent taste transduction pathway in mice. Am J Physiol Regul Integr Comp Physiol. 2015 Sep; 309(5):R552-60. Glendinning JI, Stano S, Holter M, Azenkot T, Goldman O, Margolskee RF, Vasselli JR, Sclafani A. PMID: 26157055; PMCID: PMC4591378.
    View in: PubMed Mentions: 49 Fields:
    Translation:AnimalsCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs